MICHAEL LAPINSKI: Open Payments
NPI 1902505639 · NEW BEDFORD, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$724 in 38 payments from 9 companies in 2025. Trend: 2023 $40 · 2024 $641 · 2025 $724
Food & beverage: $724
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $199 |
| Otsuka America Pharmaceutical, Inc. | 11 | $148 |
| Alkermes, Inc. | 5 | $104 |
| Axsome Therapeutics, Inc. | 3 | $88 |
| Neurocrine BioSciences, Inc. | 3 | $71 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| Janssen Pharmaceuticals, Inc | 1 | $17 |
Products named: VRAYLAR, REXULTI, Auvelity, ARISTADA, INGREZZA, FANAPT, UZEDY, CAPLYTA.
Industry payments across MA — which companies pay providers there.
